ERCC9 (also known as FANCN) encodes a DNA repair protein essential for the Fanconi anemia pathway and transcription-coupled nucleotide excision repair (TC-NER)[1]. ERCC9 works in concert with ERCC8 (CSA) in the TC-NER pathway to remove DNA lesions that block transcription. Biallelic mutations in ERCC9 cause Fanconi anemia, while variants are associated with Cockayne syndrome, premature aging, and increased cancer predisposition.
The ERCC9 protein plays a critical role in maintaining genomic integrity in post-mitotic neurons, which are particularly vulnerable to DNA damage accumulation due to their non-dividing state and high metabolic activity.
| Gene Symbol | ERCC9 (FANCN) |
| Gene Name | ERCC Excision Repair 9, Complementing |
| Chromosome | 9q33.2 |
| NCBI Gene ID | 2075 |
| OMIM | 614721 |
| Ensembl ID | ENSG00000135821 |
| UniProt ID | Q8IYD1 |
| Protein Class | DNA Repair Protein, Fanconi Anemia Pathway |
| Associated Diseases | Fanconi Anemia, Cockayne Syndrome, Cancer Predisposition |
ERCC9 is a 462-amino acid protein with several functional domains:
The protein lacks identifiable enzymatic domains and functions primarily as a scaffold, recruiting DNA repair factors to sites of transcription-blocking lesions.
ERCC9 participates in two major DNA repair pathways[2]:
TC-NER is a specialized pathway that removes DNA lesions specifically from the transcribed strand of active genes. ERCC9 functions in the following steps:
** lesion recognition**: When RNA polymerase II encounters a DNA lesion (UV-induced pyrimidine dimers, chemical adducts, oxidative damage), it stalls and recruits the CSB protein (ERCC6)
Repair complex assembly: CSB recruits the CSA complex (ERCC8 + CRRN1), which in turn recruits ERCC9
DNA damage verification: ERCC9 facilitates the assembly of the core NER machinery (XPA, XPG, XPF-ERCC1)
Dual incision and repair: Endonucleases make incisions on both sides of the lesion, and the damaged fragment is removed and replaced with new DNA
Transcription restart: After repair, the transcription machinery resumes RNA synthesis
ERCC9 (FANCN) functions as a Fanconi anemia pathway protein that coordinates DNA interstrand crosslink (ICL) repair:
ICL recognition: The FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM) localizes to DNA damage sites
Fanconi anemia pathway activation: ATR-mediated phosphorylation activates the downstream FA proteins
Rad51-mediated repair: The pathway coordinates homologous recombination to repair ICLs
Completion: The repaired DNA allows completion of DNA replication and cell division
ERCC9 is ubiquitously expressed, with highest levels in:
Within neurons, ERCC9 is primarily nuclear, concentrated in:
ERCC9 expression is highest during:
Biallelic ERCC9/FANCN mutations cause Fanconi anemia (FA)[1:1]:
| Feature | Description |
|---|---|
| Inheritance | Autosomal recessive |
| Incidence | ~1 in 350,000 births |
| Core phenotype | Bone marrow failure, congenital abnormalities |
| Cellular phenotype | Chromosomal breakage hypersensitivity |
Clinical manifestations:
Genotype-phenotype correlation: Missense mutations often result in milder phenotypes, while nonsense/frameshift mutations cause severe disease.
ERCC9 variants are associated with Cockayne syndrome (CS)[3]:
| Feature | Description |
|---|---|
| Inheritance | Autosomal recessive |
| Core phenotype | Severe neurological dysfunction, premature aging |
| Cellular phenotype | Defective TC-NER |
Clinical manifestations:
Heterozygous ERCC9/FANCN carriers have increased cancer risk:
Independent of FA and CS, ERCC9 dysfunction contributes to[4]:
Age-related neurodegeneration: Accumulation of unrepaired DNA lesions in aging neurons contributes to:
Alzheimer's disease: ERCC9 polymorphisms are associated with:
Parkinson's disease: ERCC9 variants modify:
In neurons, ERCC9 deficiency leads to[@we sunscreen2021]:
Transcription arrest: Unrepaired lesions block RNA polymerase II, causing:
Replicative stress: In dividing neural progenitors:
Genomic instability: Accumulated mutations contribute to:
ERCC9 deficiency affects mitochondrial health:
TC-NER deficiency affects chromatin:
DNA repair enhancers: Compounds that boost TC-NER efficiency:
Antioxidants: Combat oxidative DNA damage burden:
Viral vector-mediated ERCC9 delivery:
| Biomarker | Utility |
|---|---|
| γH2AX foci | DNA damage burden |
| TC-NER efficiency | Functional assay |
| Comet assay | Strand break detection |
| Plasma 8-oxodG | Oxidative damage marker |
Current research priorities[5]:
Bogliolo M, et al. Biallelic FANCN mutations cause Fanconi anemia. American Journal of Human Genetics. 2007. ↩︎ ↩︎
Marteijn JA, et al. Understanding nucleotide excision repair and its role in human disease. Nature Reviews Molecular Cell Biology. 2014. ↩︎
Fousteri M, et al. Cockayne syndrome A and B proteins regulate transcription arrest and DNA repair. Cell. 2006. ↩︎
Schlatter R, et al. DNA damage response in aging and neurodegeneration. Aging Cell. 2022. ↩︎
Kelley MR, et al. Targeting DNA repair in neurodegenerative diseases. Trends in Neurosciences. 2019. ↩︎